Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution
Merck has stepped up to help in the face of an Ebola outbreak in Uganda.
The multinational pharmaceutical company has divulged that it had developed an experimental vaccine for the Sudan strain of the Ebola virus, following previous outbreaks across Sudan and Zaire. Merck developed the Ervebo vaccine, which was approved for and used to treat the Zaire virus strain in 2019.
Since, Merck had been working on doses of an updated vaccine for potential future use. Merck have now announced that they do have an investigational version of the vaccine, and they will be producing and donating this to a global non-profit organisation's research program in Uganda for distribution to those affected by the spreading virus.
The new vaccine has not yet been tested in humans, but shows good efficacy when tested in primates. The vaccine uses a vesicular stomatitis virus vector, containing a gene that codes for a surface protein of the Sudan ebolavirus. An advantage of using this type of vaccine is that vesicular stomatitis virus self-replicates, so immunity can build very rapidly. This is similar to the vaccine that was developed for the Zaire strain of the virus, which is proven to be effective and safe in humans across regulatory bodies.
Merck are hoping this decision to donate the virus will speed along testing and production so that the vaccine can be ready for use as soon as possible.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance